Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study

BACKGROUND: Zalunfiban (RUC-4) is a novel, subcutaneously administered glycoprotein IIb/IIIa inhibitor (GPI) designed for prehospital treatment to initiate reperfusion in the infarct-related artery (IRA) before primary percutaneous coronary intervention in patients with ST-elevation myocardial infar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rikken, Sem A.O.F., Bor, Willem L., Selvarajah, Abi, Zheng, Kai L., Hack, Amy P., Gibson, C. Michael, Granger, Christopher B., Bentur, Ohad S., Coller, Barry S., van ’t Hof, Arnoud W.J., ten Berg, Jurriën M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630984/
https://www.ncbi.nlm.nih.gov/pubmed/37088164
http://dx.doi.org/10.1016/j.ahj.2023.04.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630984/
https://www.ncbi.nlm.nih.gov/pubmed/37088164
http://dx.doi.org/10.1016/j.ahj.2023.04.009

Ejemplares similares